Back to today’s briefing

Story perspectives

Nemolizumab Offers Fast Itch Relief for Eczema Patients

12/19/2025

49 4

Summary

Story summary

Nemolizumab provided rapid itch relief in patients with eczema and prurigo nodularis, per a study published December 16, 2025.
Within two days, 11% of eczema patients and 17% of prurigo nodularis patients experienced itch relief, higher than 3% and under 4% with placebo.
By two weeks, 25% of eczema patients and over 33% of prurigo nodularis patients reported significant improvements.
The study was funded by Galderma, the drug's developer.

1 of 1

Story summary

Nemolizumab provided rapid itch relief in patients with eczema and prurigo nodularis, per a study published December 16, 2025.
Within two days, 11% of eczema patients and 17% of prurigo nodularis patients experienced itch relief, higher than 3% and under 4% with placebo.
By two weeks, 25% of eczema patients and over 33% of prurigo nodularis patients reported significant improvements.
The study was funded by Galderma, the drug's developer.